Endocrine Society
Interrupted GLP-1 access? Lifestyle interventions support ongoing weight loss
Patients enrolled in an intensive lifestyle intervention program for overweight/obesity achieved clinically significant weight loss despite interruptions in access to GLP-1 drugs, according to a press release from the 2025 Endocrine Society annual meeting.
Study details. Researchers examined records for 6,392 patients who had at least 1 month of GLP-1 drug access and completed at least 1 year in a commercial intensive lifestyle intervention program for overweight/obesity. The curriculum, which included 1-on-1 coaching, focused on food, exercise, sleep, and emotional wellness.
Results. 73% of patients had at least 1 disruption in GLP-1 access; 11% had multiple disruptions. Patients with treatment disruptions achieved 14% loss of body weight in 12 months and 15% at 24 months. Patients without disruptions experienced 17% loss of body weight at 12 months and 20% at 24 months. Patients who received 1-4 treatments in 12 months achieved clinically significant weight loss at an average of 10%.
Source:
(2025, July 14). Endocrine Society. Study finds patients with interrupted GLP-1 access still achieve significant weight loss [Press release]. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/medeiros-press-release